Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity.
Kourtis LC, Regele OB, Wright JM, Jones GB. · 2019
Read Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity. by Kourtis LC, Regele OB, Wright JM, Jones GB. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6526279.txt.
Introduction
Kourtis and co-authors review digital biomarkers for Alzheimer's disease. Their review appeared in NPJ Digital Medicine. Changes in thinking, behaviour, senses and movement can precede symptoms by years. Standard tests often miss those early shifts. Costly scans and genetic tests suit research more than routine use.
Phones and wearable devices offer a cheaper route. Their sensors can track daily function in a passive way. Data can be gathered often, with little burden on clinics. The authors map early disease signs to sensor types. Each domain of change gets matched device uses. The goal is objective, high-frequency digital phenotyping. That could sharpen early cohort finding for future trials.
Catalog record
| CREATOR | Kourtis LC, Regele OB, Wright JM, Jones GB. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity By Lampros C. Kourtis, Oliver B. Regele, Justin M. Wright, Graham B. Jones Published in: NPJ Digital Medicine DOI: 10.1038/s41746-019-0084-2 ABSTRACT Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping. INTRODUCTION Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. In the USA alone, some 5 million people suffer from the disease that costs the managed healthcare system in excess of $250 billion. Currently the sixth leading cause of death, AD prevalence has increased by 89% since 2000, underscoring the need for interventive and preventative measures. Despite enormous capital investments, drug development has been problematic. It is generally accepted that the likelihood of reversing anatomic and physiologic changes (e.g., neuronal death) decreases dramatically as the disease advances, placing increased attention on early cohort discovery and patient stratification for any future clinical studies. Accordingly, there is an acute need to detect the disease at prodromal stages. In this quest for monitoring biomarkers for AD assessment, there is growing interest in the identification of readily accessible digital biomarkers, which leverage widely available mobile and wearable technologies, and it is these that are the subject of this review article. A growing body of evidence indicates that cognitive, sensory and motor changes may precede clinical manifestations of AD by several years.1 In particular, sensory and motor (non-cognitive) changes can help detect a neurological or neurodegenerative disease 10 or 15 years prior their effective diagnosis. This said, existing validated neuropsychological/cognitive tests designed to diagnose neurodegenerative diseases are often less effective in detecting deviations from normal cognitive trajectory in the earliest stages of the disease. Furthermore, cognitive tests can suffer from intrinsic cultural bias, take a relatively long time to administer, provide only episodic information, show “practice effect” or “ceiling effect,” and are rater dependent.2 Explorations into the inclusion of genetic testing, structural MRI imaging and PET molecular imaging of beta-amyloid and tau protein promise earlier detection of disease, though these tests are currently limited to research applications due to their cost and invasive nature. These limitations preclude repeated and frequent use to test an individual and specifically in the early pre-symptomatic stage. Mobile and wearable digital consumer technology has the potential to overcome these limitations, and their application in AD detection has become an area of increased interest. MOBILE AND WEARABLE DEVICE- DERIVED DATA Mobile and wearable technologies (such as smart phones, tablets, smart watches, and rings, smart suits) present a unique opportunity to massively detect neurodegenerative diseases in a timely and economical fashion due to: a) the widespread usage of such technologies b) the immediate access of information due to the inherent connectivity c) the increasing sensitivity and plurality of onboard sensors d) the nature of these sensors that are uniquely equipped to study such physical and cognitive abilities or symptoms e) the extremely low burden on the healthcare system, since these devices are increasingly in use by large segments of the population. Onboard sensors at the heart of these systems are able to provide metrics by means of active (prompted) or passive (unnoticed) measurements, offering considerable flexibility in approach. Active data collection occurs when a user is prompted to perform a measurement and/or enter a metric value, e.g., a digital e-assessment cognitive test that probes memory on a tablet to detect AD,3 or a prompted voice test that probes vocal cord tremor to detect PD.4 These measurements are usually targeted at addressing specific metrics that have previously been correlated with the disease. Passive data collection occurs when metric values are acquired unbeknownst to the user, e.g, a smartwatch-based step counter that continuously estimates step symmetry and length or a smart ring-based continuous heart rate monitor that picks up heart rate variability (HRV). As such, daily interaction with mobiles/wearables can result in a rich, high-frequency longitudinal data set that can be mined for signatures of a disease—while using users as their own control. Passive data collection has several advantages, including,high frequency or even continuous data acquisition,objectivity (not influenced by user perspective and learning effects),low patient burden, which can lead to higher adherence. On the other hand, passive data collection maybe limited to particular metrics that can be collected non-actively,be expensive computationally and storage wise,requires complex analysis tools to extract useful information. These issues notwithstanding, given the decline in cognitive function and memory experienced by AD patients, passive data collection provides a logical approach for developing methods for disease forecasting, detection and monitoring. An enormous opportunity is presented for technology developers and healthcare professionals to ideate on new clinical studies which can provide insights to both disease detection and symptom assessment. This review article considers disease-relevant aspects of sensor and device design, data collection modalities, and a path to clinical grade digital phenotyping. A non-exhaustive summary of available sensors or digital senses on each wearable/mobile device is presented in Fig. 1.Fig. 1Consumer wearable and mobile devices offer a large personalized, direct, and high frequency sensing potential. Microphones can sense ambient noise and voice. Touch screens can probe for fine motor skills in swiping and typing. Cameras can register eye movements, gaze, and pupillary reflexes as well as capture facial expression traits. Altimeters offer useful information with respect to activity and barometers provide atmospheric pressure readings and weather data. PPG (Photoplethysmography) provides beat-to-beat heart rate measurements (HRM), heart rate variability (HRV) and oxygen saturation (SpO2). IMU (Inertia Measurement Unit) includes accelerometer, gyroscope and magnetometer (9 spatial values) and is used by numerous applications to track activity. Geopositioning sensors (GPS and WiFi localization) provide accurate location information. Light sensors read ambient visible or UV radiation levels. Thermometers on rings, patches or watches provide body temperature readings. Electromyograph sensors (EMG) found on patches or suits yield muscle group activity signals. Electrodermograph (EDG) or Galvanic Skin Response (GSR) sensors equip patches and watches to measure the skin conductance and potential or the skin resistance/impendance. Social interactions can be monitored using proximity to Bluetooth or Wi-Fi enabled devices as well as by monitoring overall phone use (calls, texts) and social network activity. Finally, wearable/mobile devices are equipped with logic components that can probe the executive function and memory of a user DISEASE SPECIFIC METRICS AND SENSORS Sensor signals can individually or collectively provide metrics that can determine aspects of a domain that is affected by a particular disease or condition (Table 1)Table 1List of sensors and their respective domains and metricsSensorMetricsSense—DomainReferenceCameraSaccades, saccades in readingOcculomotor—eye movements 5, 30– 32 Novelty preferenceOcculomotor—eye movements 22, 27 Constriction